# Prepared for

World Obesity Federation

October 2016

## **OBESITY: A CHRONIC RELAPSING PROGRESSIVE DISEASE PROCESS**

# George A. Bray, M.D. John P.H. Wilding DM FRCP, Leonard Kim, MD for the World Obesity Federation

# Pennington Biomedical Research Center, Baton Rouge, LA 70808

Obesity and Endocrinology Research, University of Liverpool, UK

Korea

# KyoungKon Kim (Leonard) zaduplum@aim.com

Wilding, John <J.P.H.Wilding@liverpool.ac.uk>

# Words: 2404

# Running Title: Obesity: a chronic disease process

Address Correspondence to:

George A. Bray, M.D.

Pennington Biomedical Research Center

6400 Perkins Road

Baton Rouge, LA 70808

Abstract:

 This paper considers the argument for obesity as a chronic relapsing disease process. Obesity is viewed from an epidemiological model, with an agent affecting the host and producing disease. Food is the primary agent, particularly foods that are high in in energy density such as fat, or in sugar-sweetened beverages. An abundance of food, low physical activity and several other environmental factors interact with the genetic susceptibility of the host to produce positive energy balance. The majority of this excess energy is stored as fat in enlarged, and often more numerous fat cells, but some lipid may infiltrate other organs such as the liver (ectopic fat). The enlarged fat cells and ectopic fat produce and secrete a variety of metabolic, hormonal and inflammatory products that produce damage in organs such as the arteries, heart, liver, muscle, and pancreas. The magnitude of the obesity and its adverse effects in individuals may relate to the virulence or toxicity of the environment and its interaction with the host. Thus, obesity fits the epidemiological model of a disease process except that the toxic or pathological agent is food rather than a microbe. Reversing obesity will prevent most of its detrimental effects.

# Introduction:

 The question of whether obesity, which affects are large fraction of the world’s population, should be called a “disease” has sparked controversy for most of the last century and into the 21st century (NIH 1985; Downey 2001; Bray 2004; Allison et al 2008; Kyle et al 2016; Church 2016). As Faber noted 70 years ago, “All disease entities are abstract concepts created by the human mind” (1923), and this would include obesity. A timeline for the differences of opinion about whether obesity is a disease process from 1977 shows gradual movement towards acceptance of the proposition that obesity is a disease process (Kyle et al 2016). In 1977 the American Health Care Financing Administration decided obesity was not a disease (Kyle et al 2016). In 2002, the Japanese Association for the Study of Obesity published criteria applicable to their population on criteria for obesity as a disease process (JASSO 2002). In 2004 the Centers for Medicare and Medicaid Services (CMS) in the United States removed language saying obesity was not a disease (Kyle et al 2016). In 2010, the Scottish Intercollegiate Guideline (SIGN 2010) used these words to describe obesity: “Obesity is defined as a disease process characterised by excessive body fat accumulation with multiple organ-specific consequences.” Only 3 years later, in 2013, The American Medical Association recognized obesity as a disease (Kyle et al 2016). This was followed in short order by a number of other health professional organizations recognizing obesity as a disease process, including The American Association of Clinical Endocrinologists, the American Academy of Family Physicians, the American College of Cardiology, the American College of Surgeons, the American Society for Reproductive Medicine, the American Urological Association, the Endocrine Society, the Obesity Society, the Society for Cardiovascular angiography and Interventions (ASMBS 2013) and by World Health Organization, the Food and Drug Administration and the National Institutes of Health. (Garvey WT, et al 2016); Garvey WT et al 2014). Finally, in 2015, the "Nagoya Declaration called "Obesity as a disease" capping this international chorus referring to “obesity as a disease (process)” (Nagoya 2015).

The World Obesity Federation is an organization representing professional societies from many countries that focus on research, education and health care for people with obesity. The World Obesity Federation has commissioned this statement to argue for the position that “Obesity is a chronic relapsing disease process” and to serve as the basis for their position on this issue.

#

The chronic and relapsing nature of obesity are illustrated in

figure 1 redrawn from the Diabetes Prevention Program and Outcomes Study, an on-going study of individuals with at risk for developing diabetes (Venditti EM, et al 2008). The initial body mass index of the placebo group was 30.4 kg/m2 and it showed little change over the 10 year interval. The same is seen over a 15 year interval in the matched control group with obesity from the Obese Subjects Study (Sjöström L, et al 2007). In the Look AHEAD trial that enrolled people with diabetes and obesity, the initial body mass index of 36.0 kg/m2 did not change more than 3% over 10 years (The Look AHEAD Research Group; (Wing RR, et al 2013)

The relapsing nature of this disease process is also seen in Figure 1 where the treatment group initially lost over 7 kg and then slowly regained over 70% of the lost weight over the next 4 years. This long-term stability of body weight without treatment intervention suggests the existence of a set-point or settling point mechanism where changes in food intake are a major driver of the change in body weight (Hall & Guo 2017).

Not only does obesity relapse, but in the early years prior to the plateau seen in figure 1, there is progressive weight gain. In those who become obese, the increase in weight occurs over many years. In the CARDIA study, for instance, there was a weight gain of 7.8 kg over an 8 year period in individuals who were aged 18-30 years. (Folsom, A et al. 1999).

One difficulty with weight loss is that it activates a number of hormonal changes that favor weight regain ([Sumithran P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sumithran%20P%5BAuthor%5D&cauthor=true&cauthor_uid=22029981), et al 2011). One of the most challenging questions remaining to be solved is why long-term weight loss is so difficult to sustain and how these compensatory mechanisms can be disabled or overcome.

Few will argue with the proposition that obesity, or excess body fatness, whether estimated by skin fold thicknesses (Sievenpiper et al 2001), by weight in relation to height (BMI)(Jensen et al 2014), by waist circumference (Cerhan et al 2014) or by more sophisticated techniques including dual x-ray absorptiometry (DXA)(Bray et al 2001), magnetic resonance imaging (MRI) (Al-Gindan et al 2015) or computed tomography (CT)( Bray et al 2008) or other measures poses an increased risk of mortality in individuals with obesity (Whitlock et al 2009; Berrington et al 2010; Cerhan et al 2014; Boggs et al 2011) and morbidity (Bray 2011; Bray et al 2016; Sjostrom et al 1997; Jensen et al 2014). Obesity also increases health care costs for society (Cawley et al 2012; Loeppke et al 2009; Tsai et al 2013; Finklestein et al 2014; Finkelstein et al 2012; Wang et al 2011).

 We will argue that obesity is a disease process in the same sense that hypertension or hypercholesterolemia are diseases. Weight, like blood pressure and cholesterol are continuous variables (Fig 2).

-----------------------------

Figure 2 about here.

----------------------------

When each of these variables deviates sufficiently above the population mean as shown by the vertical dashed line it produces a disease; this is called hypertension when blood pressure is too high, hypercholesterolemia when cholesterol is too high or obesity when body weight is too high. Obesity is no different from these other chronic diseases where short term treatments do not change the underlying biology that drives and maintains them. Garrow caught the essence of obesity when he said that:

“Obesity is not a disease which you either do or do not have: rather it is a continuum, like baldness, in which the diagnosis is made when some arbitrary diagnostic boundary is exceeded. (Garrow 1981)”

The importance of this deviation was captured even earlier by Dr

Malcolm Flemyng when he said more than 250 years ago:

 *“Corpulency, when in an extraordinary degree, may be reckoned*

 *as a disease, as it in some measure obstructs the free exercise*

*of the animal functions; and hath a tendency to shorten life,*

*by paving the way to dangerous distempers.”*  (Flemyng 1760)

Over the years since then obesity has been recognized as a disease process many, many times (Wadd 1816; NIH The National Institutes of Health 1985; Bray 2004; Allison 2008; AMA June 2013; Mechanick 2012).

One concern about labelling obesity as a disease process is the finding that some people with obesity do not have any of the risk factors for associated diseases although they may be victims of stigmatization and at risk for orthopaedic problems. These so-called “healthy obese” have no “associated” risk factors such as prediabetes, dyslipidemia, hypertension or other findings. (Wildman et al 2008) However, it is now clear from long-term follow-up studies that half or more of these individuals will develop obesity related disease during their lifetime (Kramer et al 2013). This effect of time on the expression of risk factors in people with higher body weight (i.e., obesity) is clearly seen in data from the Framingham study where the mortality was followed in 6 year intervals for 30 years from the initial examinations in 1948-50. The relative risk of mortality is plotted against the baseline relative weight (Figure 3). For the first 12 years the heavier group had a lower mortality than lighter individuals. As time passed, however, the curvilinear relationship between relative weight and mortality appeared at 18 years and got progressively stronger (Batsis et al 2014). By 26 years, Hubert et al (1983) could claim that obesity was an independent risk factor for heart disease. Thus, quoting from Garrow again, we need to “Treat Obesity Seriously” (1981) and provide sufficient time for efforts at prevention and treatment to work.

The curvilinear relationship of BMI to body weight appears to be contradicted by the finding that elderly individuals and those with specific diseases such as chronic obstructive pulmonary disease (COPD), heart failure obesity may contribute to longer life, a finding called the “Obesity Paradox”. The explanation is probably a consequence of selection bias. A simple way to eliminate this bias is to ensure the start of exposure and the start of follow-up coincide. This is precisely how randomized clinical trials are typically analyzed: an analysis that selects individuals free of coronary heart disease five years after randomization and then compares the coronary heart disease incidence between arms from year 5 onwards would be unacceptable. Similarly for the effect of obesity. (Lajous M et al 2015).

----------------------

Figure 3 about here (Framingham curves)

----------------------

**An Epidemiological Model**

An epidemiological model for obesity as a chronic progressive relapsing disease process is shown in Figure 4 (Nordsiek 1964; Bray 2006). An epidemiological model has an environmental agent that acts on a host to produce a disease. Disease is related to the virulence of the agent and the susceptibility of the host.

----------------------------

Figure 4 Epidemiological models: Panel A the Epidemiological model: Panel B some of the agents that act on the host to modify food intake and physical activity.

---------------------

**The Agent**

Food is the principal environmental agent for obesity, with a decline in the level of physical activity being second (Putnam JJ et al 1997; Scully 2014). Tasty, low cost, convenient foods are abundant in the western diet (Moss 2013; Bray 2014). These tasty foods can activate the so-called pleasure centers of the brain providing pleasurable rewards from eating (Pandit et al 2012; de Macedo et al 2016). This center is the same one that is activated by substances of abuse. (Bray 2016) At the same time that tasty foods have become less expensive and more abundant, physical activity has gradually declined (Church et al 2012) and together with the abundance of food provide the major drivers for obesity.

In addition to food and physical activity, a variety of other environmental factors such as less sleep time, endocrine disruptors (also called obesogens)(Janesick et al 2014), epigenetic and intergenerational effects, older parental age, certain medications and reduced smoking have all conspired to enhance the effects from the main causative agents – tasty and pleasurable food and low physical activity (Keith et al 2006)

**The Host:**

Genetic Factors

Genetic factors are a component of the host response to the environmental agents. There are some genes which have high penetrance and lead inevitably to massive obesity. Examples would be defects in the production of leptin or a defective leptin receptor, abnormalities in proopiomelanocortin (POMC) gene, or in the melanocortin-4 receptor system (Loos 2012; Farooqi and O’Rahilly 2007). However, nearly 100 other genes have been identified that are related to obesity and fat distribution, but with a much smaller individual contribution (Locke et al 2015; Shungin et al 2015). It is clear that in the same environment some people become obese and others don’t. Many factors are involved in this differential response and some of them have been noted above.

**Fat Cells**

For the genetically susceptible host, excess energy from food leads to an accumulation of fat in fat cells (Halberg et al 2008). The enlargement and/or increase in number of fat cells to accommodate this storage of fat are the pathologic lesions of obesity. The distribution of fat in ectopic regions such as visceral fat, cardiac fat, and fat in muscles may occur as fat cells reach their maximal storage capacity. Enlarging fat cells and the microbiome may interact to increase the inflammatory environment of the host (Rosenbaum M, et al 2015).

As the fat cells increase in size they produce increased amounts of a variety of peptides, including leptin, cytokines such as interleukin 6 and tumour necrosis factor alpha, angiotensinogen, adipsin (Complement D), metabolites such as free fatty acids and lactate; concentrations of the anti-inflammatory adipocyte product, adiponectin fall (Arita et al 2012).The products of the fat cell in turn modify the metabolic and inflammatory processes in the host affecting the brain and peripheral systems alike (Hallberg et al 2007). For the susceptible host, these metabolic changes lead in turn to a variety of other processes, including dyslipidaemia, hypertension hyperinsulinemia and diabetes, resulting in atherosclerosis, and physical stress on bones and joints (Figure 5). However, not everyone with hypertension develops a stroke and not everyone with who is obese develops serious outcomes. From this epidemiological perspective, we conclude that obesity is a disease process in the same way that atherosclerosis and hypertension are diseases and that like these diseases may require long-term treatment.

**The Pathologic Changes Associated with Obesity: The Disease**  **Process**

The enlarged fat cells produce the physical signs of obesity. The metabolic consequences of obesity result from the cytokines released from fat cells and from the inflammatory environment in which they live.

--------------------

Figure 5 about here

--------------------

Figure 5 provides a model of the intermediary mechanisms for each of the major manifestations of obesity that we will deal with below, including diabetes mellitus, myocardial infarction, hypertension and stroke, some forms of cancer, sleep apnea, gallstone disease, osteoarthritis, neurodegenerative diseases and stigmatization.

 Two types of functional impairments are associated with the increased size and mass of fat cells in obesity. The first are those related to the fat mass such as osteoarthritis (Bray 2011), sleep apnea(Wall et al 2012; Li et al 2010 ), and the psychosocial responses to the individual with obesity(Bray 2011). The second are the metabolic and inflammatory consequences resulting from the excessive secretion of products by the enlarged fat cell (Halberg et al 2008) and ectopic deposition of lipid (Neeland et al 2013).

Leptin is one of many proteins secreted in larger amounts by enlarging fat cells. Leptin deficiency, a recessively inherited genetic disease, produces massive obesity in human beings and animals as its principal sign and symptom (Loos 2012; Farooqi & O’Rahilly 2007). The increased concentration of free fatty acids, which also rises as the size of the fat cell increases, probably produces alterations in insulin clearance by the liver and the altered metabolism of cholesterol in the liver that lead to the increasing risk of diabetes and gall bladder disease in the obese (Bonafrate et al 2014).

For all of these pathologic states the relationship between increasing body weight or body mass index and disease is curvilinear. That is, as body weight or BMI increase, the risk for diabetes (DeFronzo et al 2015; Hu et al 2004), gall bladder disease (Bray 2011; Bonafrate et al 2014), cardiovascular disease, and cancer increases as the excess weight deviates ever more from the median (Figure 1). A study of BMI and mortality done by pooling many studies, mainly from Europe (Whitlock et al Lancet 2009) showed that the optimal BMI for lowest mortality was between 22.5 and 25 kg/m2. For each increase of 5 BMI units total mortality rose by 30%, chronic kidney disease by 60% and diabetes mellitus by 120%. This relationship between BMI and risk for death has been confirmed repeatedly (Berrington et al 2010; Boggs et al 2012). BMI is one predictor of risk and body fat another. When these two were examined together in a large Canadian population assembled from people who had a DXA to measure bone mineral density, Padwal et al (2016) found that low BMI and high body fat percentage are independently associated with increased mortality which may help explain the counterintuitive relationship between overweight and obesity.

**Diabetes mellitus**

Obesity is one of the strongest predictors of Type 2 diabetes (Menke) et al 2014). Development of type 2 diabetes thus depends on changes in one or both of these two principal variables – insulin sensitivity and insulin secretion. Obesity can modify one or both of these variables (DeFronzo et al 2015).

In the individual with diabetes, the mass of beta-cells is reduced, probably by apoptosis. In addition chronic exposure to high levels of glucose may blunt the responsiveness of these cells to incretins (DeFronzo et al 2015) and thus their ability to keep up with the demand for insulin to facilitate glucose uptake peripherally. Multiple factors contribute to the failure of the beta-cell including resistance to incretin hormones (GIP and GLP-1), lipotoxicity, glucotoxicity, ageing, genetic abnormalities, increased secretion of islet amyloid polypeptide, reactive oxygen stress, and inflammation (DeFronzo et al 2015).

Epigenetic Factors

The intrauterine environment provides a mechanism that predisposes some people with obesity to develop diabetes later in life. Individuals who were malnourished while *in utero* may be more prone to weight gain, insulin resistance, beta-cell failure and hence diabetes than those who are well nourished, an hypothesis known as the “Developmental Origin of Disease” (DOoD) or the “Barker Hypothesis” (Barker et al 2002). Maternal undernutrition forces the fetus to adapt during its intrauterine development and drives a reprogramming of its endocrine–metabolic state to produce permanent changes in the structure and the physiology of key organ systems [Barker et al 2002; Godfrey et al 2010]. These changes in low-birth-weight infants (normal range, 3000–4000 g) contribute factors to chronic diseases such as type 2 diabetes, coronary heart disease, stroke, and hypertension in adult life [Kanaka-Gantenbein C, 2010).

**Cancer:**

Obesity predicts the development of some forms of cancer, particularly in women (Calle et al 2003). Estrogen production by adipose tissue and the associated risk of endometrial and breast cancer is well known. In post-menopausal women adipose tissue is the major source of estrogenic compounds since the ovaries no longer produce estrogens. (Figure 5) In addition, the growth factors produced by adipose tissue such as fibroblast growth factor-21 (FGF-21), nerve growth factor (NGF), transforming growth factor-β (TGFβ), and vascular endothelial growth factor (VEGF), as well as insulin, may also participate in the growth of cells that eventually become malignant contributing another component to the risk for diverse forms of cancer in the individual who is obese (Hvidtfeldt et al 2012)

**Hypertension, Stroke, and Cardiovascular Disease**

Hypertension, stroke, and cardiovascular diseases are also increased in obesity (Yatsura et al 2010). Several mechanisms may be involved in the development of hypertension, stroke and cardiovascular disease in these patients. The pro-inflammatory and pro-thrombotic adipokines may contribute to increased cardiovascular disease risk (Schnabel et al 2013). Increased vascular volume, greater arterial resistance and the release of angiotensinogen from enlarged fat cells may contribute to the higher blood pressure.

**Sleep Apnea**

The prevalence of sleep apnea is increased in the patient with obesity (Li et al 2010). Accumulation of fat in the pharynx is a major risk factor for development of sleep apnea which occurred in 80% of the participants enrolled in the sleep substudy in the Look AHEAD trial (Foster et al 2009). In severe cases, ‘obesity hypoventilation’ can develop, which is a debilitating state of intermittently impaired consciousness, exemplified by Joe in Dickens’ Pickwick Papers.

**Gallstone Disease**

Gallstone disease is more prevalent in the patient with obesity. Increasing body fat increases the turnover of cholesterol (Bray 1976) such that each kilogram of extra body fat produces an extra 20 mg of cholesterol each day which must be secreted through the biliary tree. For individuals with a tendency to gall stone formation, this extra load of cholesterol from increased fat may be the tipping point for the development of stone formation and gall bladder disease (Radmard et al 2015).

**Osteoarthritis**

Osteoarthritis is more prevalent in people who are obese (Reyes et al 2016). This can involve both weight bearing and non-weight bearing joints, suggesting that the pathophysiology must involve both the increased body mass (figure 5), circulating adipokines, inflammatory factors or other pathophysiologic mechanisms.

**Stigmatization**

Body size provides a visual read-out to the observing the individual about the size of the person they are seeing. Many people with obesity do not perceive their enlarged size, but this is readily perceived by external observers and plays a dominant role in the stigmatization of obesity in children (Latner & Stunkard 2003) and adults (Puhl & Latner 2007) by both the general public and by health professionals alike. This may lead to discrimination and contribute to depression and anxiety.

Although obesity is a non-communicable disease process (NCD), the epidemiological model of obesity described above tells us that it has a number of features in common with a “communicable disease” including environmental agents, and the host responses to these agents. Just as infectious diseases have been controlled primarily by change in the environment such as improved sanitation, the control of obesity epidemic should start by controlling the virulence of environmental agent, which can be done by a collaboration of obesity professionals, local health environment authorities and industry. Early diagnosis and treatment of childhood obesity could be considered similar to vaccination, by targeting individuals from the day of birth. A healthy body weight and healthy lifestyle should be implemented from early stages in life. For preventing damage to the host from obesity medical personnel play an important role in the evaluation and treatment of the comorbidities in people with obesity.

Continuous effort is needed to control obesity because it is a relapsing disease process. There are many background genetic factors related to body weight and body fat which modify the responses to the tasty, inexpensive and convenient food in the environment. Removing barriers to physical activity provides an additional approach which may be analogous to the use of antibiotics for infectious diseases. With continuous and comprehensive efforts the obesity epidemic will be gradually brought under control.

The World Obesity Federation takes the position that obesity is a chronic, progressive, relapsing disease process and emphasizes the need for immediate action for prevention and control of this global epidemic.

**Legends**:

Figure 1: Weight change over 10 years in the Diabetes Prevention Program. The Lifestyle Arm of this trial initially lost weight to reach a nadir at 1 year and then regain 70 percent of the lost weight compared to the nearly stable weight of the placebo group. Redrawn and adapted from Venditti et al Int J Obes (Lond). 2008;32(10):1537-44

Figure 2: Relationship of body mass index (BMI), cholesterol and diastolic blood pressure to relative risk of mortality. Data from the American Cancer Society Study (Lew & Garfinkel 1979) have been replotted for the BMI, and tables in papers by Stamler et al (1986, 1989) have been used to construct the relationship between cholesterol and blood pressure. (Bray 1996)

Figure 3: Mortality for Women in the Framingham Study in relation to initial relative weight plotted for each 6 years of observation

Figure 4 Panels A and B: An epidemiological model of obesity. Panel A shows the basic elements for an epidemiological model – Agent, host and disease. Panel B shows the variety of environmental agents that have been related to the onset of obesity (Bray 2011)

Figure 5: A model showing the relation of obesity in the center and the diseases with which it is associated. The intermediate boxes show the pathophysiological factors that are principally involved with the development of disease; many of these pathophysiological factors may interact and be involved in more complex causal pathways, but potential interactions have been omitted for clarity.

**References**

Al-Gindan YY, Hankey CR, Govan L, Gallagher D, Heymsfield SB, Lean ME. Derivation and validation of simple anthropometric equations to predict adipose tissue mass and total fat mass with MRI as the reference method.Br J Nutr. 2015 Dec 14;114(11):1852-67.

Allison DB, M, Downey, R.L. Atkinson, C.J. Billington, G.A. Bray, R.H. Eckel, E.A. Finkelstein, M.D. Jensen, A. Tremblay. [Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society.](http://www.ncbi.nlm.nih.gov/pubmed/18464753?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Obesity (Silver Spring). 2008;16:1161-77.

ASMBS. (American Society for Metabolic and Bariatric Surgery). http:/asmbs.org/2013/06/obesity-is-a-diseae-leading-obesity-groups-agree/.Accessed September 11, 2013

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y.

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochem Biophys Res Commun. 2012 Aug 31;425(3):560-4.

[Barker DJ](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Barker%20DJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Eriksson JG](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Eriksson%20JG%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Forsén T](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Fors%C3%A9n%20T%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract), [Osmond C](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Osmond%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract). Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol. 2002 Dec;31(6):1235-9.

Batsis JA, Sahakyan KR, Rodriguez-Escudero JP, Bartels SJ, Lopez-Jimenez F.

[Normal weight obesity and functional outcomes in older adults.](http://www.ncbi.nlm.nih.gov/pubmed/24909976) Eur J Intern Med. 2014 Jul;25(6):517-22.

Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Sulver H, Greeman LB, Geeson WL, Clipp SL, English DR, Folsome AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton, J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ. Body-mass index and mortality among 1.46 million white adults. NEJM 2010;363:2211-2219.

Boggs DA, Rosenberg L, Cozier YC, Wise LA, Coogan PF, Ruiz-Narvaez EA, et al. General and abdominal obesity and risk of death among black women. N Engl J Med. 2011; 365:901-8.

Bonfrate L, Wang DQ, Garruti G, Portincasa P Obesity and the risk and prognosis of gallstone disease and pancreatitis. Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):623-35.

.

Bray, G.A. *The Obese Patient*. Major Problems in Internal Medicine, Vol 9, Philadelphia, Pa.: W.B. Saunders Company, 1976, pp. 1-450.

Bray, G.A. Coherent preventive and management strategies for obesity. IN: *The Origins and Consequences of Obesity*. D.J. Chadwick and G. Cardew (ed). Ciba Foundation Symposium 201. London: John Wiley, 1996 pp 228-246.

Bray, G.A. Obesity is a chronic, relapsing neurochemical disease. Intern J Obes 28: 34-38, 2004.

Bray, G.A. Obesity: the disease. J Med Chem 2006;49:4001-7.

Bray G.A. *A Guide to Obesity and the Metabolic Syndrome: Origins and Treatment.* New York: CRC Press: Taylor and Francis Group. 2011

Bray, GA. From Farm to Fat Cell: Why Aren't We All Fat? Metabolism. 2015 Mar;64(3):349-53.

Bray GA. Is Sugar Addictive? Diabetes. 2016 Jul;65(7):1797-9.

Bray GA, DeLany JP, Harsha DW, Volaufova J, Champagne CM. Evaluation of body fat in fatter and leaner 10-y old African-American and white children: the Baton Rouge Children’s Study. Am J Clin Nutr 2001;73:687-702.

Bray GA, Fruhbeck G, Ryan DH, Wilding JPH. Management of Obesity. Lancet 2016 Aug 20;388(10046):759-60.

Bray GA, Jablonski KA, Fujimopto WY, Barrett-Connor E, Haffner S, Hanson RL, Hill JO, Hubbard V, Kriska A, Stamm E, Pi-Sunyer FX, Diabetes Prevention Program Research Group. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr 2008 May;87(5):1212-1218.

[Cawley J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cawley%20J%5BAuthor%5D&cauthor=true&cauthor_uid=22094013), [Meyerhoefer C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Meyerhoefer%20C%5BAuthor%5D&cauthor=true&cauthor_uid=22094013) The medical care costs of obesity: an instrumental variables approach. [J Health Econ.](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Journal+of+health+economics%22%5BJour%5D+AND+31%5Bvolume%5D+AND+219%5Bpage%5D&cmd=detailssearch) 2012 Jan;31(1):219-30.

Calle, E. E., C. Rodriguez, et al. "Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults." N Engl J Med 2003; 348(17): 1625-38.

Cerhan JR, Moore SC, Jacobs EJ, et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc 2014;89:335-345.

Church TS, Thomas DM, Tudor-Locke C, Katzmarzyk PT, Earnest CP, Rodarte RQ, Martin CK, Blair SN, Bouchard C. [Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity.](http://www.ncbi.nlm.nih.gov/pubmed/21647427) PLoS One. 2011;6(5):e19657.

Church TS. [Why obesity should be treated as a disease.](http://www.ncbi.nlm.nih.gov/pubmed/25014383) Curr Sports Med Rep. 2014 Jul-Aug;13(4):205-6.

DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R. [Type 2 diabetes mellitus.](http://www.ncbi.nlm.nih.gov/pubmed/27189025) Nat Rev Dis Primers. 2015 Jul 23;1:15019.

de Macedo IC, de Freitas JS, da Silva Torres IL. The Influence of Palatable Diets in Reward System Activation: A Mini Review. Adv Pharmacol Sci 2016;2016:7238679

Downey MB. Obesity is a disease entity. Am Heart J 2001;142:1091-1094.

Faber K. *Nosography in Modern Internal Medicine*. New York: Paul B. Hoeber, Inc.; 1923.

Farooqi, I. S. and S. O'Rahilly. Genetic factors in human obesity. Obes Rev 2007. 8 Suppl 1: 37-40.

Finkelstein EA, Graham WC, Malhotra R. Lifetime direct medical costs of childhood obesity. Pediatrics 2014;133:854-862.

[Finkelstein EA](http://www.ncbi.nlm.nih.gov/pubmed/?term=Finkelstein%20EA%5BAuthor%5D&cauthor=true&cauthor_uid=22608371)1, [Khavjou OA](http://www.ncbi.nlm.nih.gov/pubmed/?term=Khavjou%20OA%5BAuthor%5D&cauthor=true&cauthor_uid=22608371), [Thompson H](http://www.ncbi.nlm.nih.gov/pubmed/?term=Thompson%20H%5BAuthor%5D&cauthor=true&cauthor_uid=22608371), [Trogdon JG](http://www.ncbi.nlm.nih.gov/pubmed/?term=Trogdon%20JG%5BAuthor%5D&cauthor=true&cauthor_uid=22608371), [Pan L](http://www.ncbi.nlm.nih.gov/pubmed/?term=Pan%20L%5BAuthor%5D&cauthor=true&cauthor_uid=22608371), [Sherry B](http://www.ncbi.nlm.nih.gov/pubmed/?term=Sherry%20B%5BAuthor%5D&cauthor=true&cauthor_uid=22608371), [Dietz W](http://www.ncbi.nlm.nih.gov/pubmed/?term=Dietz%20W%5BAuthor%5D&cauthor=true&cauthor_uid=22608371). Obesity and severe obesity forecasts through 2030. [Am J Prev Med.](http://www.ncbi.nlm.nih.gov/pubmed?term=42%5Bvolume%5D+AND+563%5Bpage%5D+AND+Finkelstein+EA%5Bauthor%5D&cmd=detailssearch) 2012 Jun;42(6):563-70.

Flemyng, M. *A discourse on the nature, causes and cure of corpulency. Illustrated by a remarkable case, read before the Royal Society, November 1757 and now first published*. London: L. David and C. Reymers; 1760.

Folsom AR, Jensen MD, Jacobs DR, Hilner JE, Tsai AW, Schreiner PJ. “Serum Leptin and Weight Gain Over 8 Years in African American and Caucasian Young Adults.” *Obesity Research* 1999;7: 1–8

[Foster GD](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Foster%20GD%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Sanders MH](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Sanders%20MH%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Millman R](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Millman%20R%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Zammit G](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Zammit%20G%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Borradaile KE](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Borradaile%20KE%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Newman AB](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Newman%20AB%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Wadden TA](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Wadden%20TA%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Kelley D](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Kelley%20D%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Wing RR](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Wing%20RR%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Sunyer FX](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Sunyer%20FX%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Darcey V](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Darcey%20V%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), [Kuna ST](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Kuna%20ST%22%5BAuthor%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus); [Sleep AHEAD Research Group](file:///%5C%5Cpbrc.edu%5Cfiles%5CUsers%5Cbrayga%5CBrayga%20Laptop%20Files%2005.May.18%5Csites%5Centrez%3FDb%3Dpubmed%26Cmd%3DSearch%26Term%3D%22Sleep%20AHEAD%20Research%20Group%22%5BCorporate%20Author%5D%26itool%3DEntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus). Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care 2009;32:1017-1019

Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D,

Grunberger G, Handelsman Y, Hennekens CH, Hurley DL, McGill J, Palumbo P, Umpierrez G, On Behalf Of The AACE Obesity Scientific Committee. [American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on obesity: building an evidence base for comprehensive action.](http://www.ncbi.nlm.nih.gov/pubmed/25253226) Endocr Pract. 2014 Sep 1;20(9):956-76.

Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016 Jul;22 Suppl 3:1-203.

Garrow JS. *Treat obesity seriously: A Clinical Manual*. New York: Churchill Livingstone; 1981.

Godfrey KM, Gluckman PD, Hanson MA. Developmental origins of metabolic disease: life course and intergenerational perspectives. Trends Endocrinol Metab. 2010 Apr;21(4):199-205.

Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am. 2008 Sep;37(3):753-68)

Hall K Guo. Gastroenterology 2017

[Hu G](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hu%20G%5BAuthor%5D&cauthor=true&cauthor_uid=15111376), [Lindström J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Lindstr%C3%B6m%20J%5BAuthor%5D&cauthor=true&cauthor_uid=15111376), [Valle TT](http://www.ncbi.nlm.nih.gov/pubmed/?term=Valle%20TT%5BAuthor%5D&cauthor=true&cauthor_uid=15111376), [Eriksson JG](http://www.ncbi.nlm.nih.gov/pubmed/?term=Eriksson%20JG%5BAuthor%5D&cauthor=true&cauthor_uid=15111376), [Jousilahti P](http://www.ncbi.nlm.nih.gov/pubmed/?term=Jousilahti%20P%5BAuthor%5D&cauthor=true&cauthor_uid=15111376), [Silventoinen K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Silventoinen%20K%5BAuthor%5D&cauthor=true&cauthor_uid=15111376), [Qiao Q](http://www.ncbi.nlm.nih.gov/pubmed/?term=Qiao%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=15111376), [Tuomilehto J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Tuomilehto%20J%5BAuthor%5D&cauthor=true&cauthor_uid=15111376). Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation. [Arch Intern Med.](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Archives+of+internal+medicine%22%5BJour%5D+AND+164%5Bvolume%5D+AND+892%5Bpage%5D&cmd=detailssearch) 2004 Apr 26;164(8):892-6.

Hubert HB, Feinleib M, McNamara PM, Castelli WP. [Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.](http://www.ncbi.nlm.nih.gov/pubmed/6219830) Circulation. 1983 May;67(5):968-77.

[Hvidtfeldt UA](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hvidtfeldt%20UA%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Gunter MJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gunter%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Lange T](http://www.ncbi.nlm.nih.gov/pubmed/?term=Lange%20T%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Chlebowski RT](http://www.ncbi.nlm.nih.gov/pubmed/?term=Chlebowski%20RT%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Lane D](http://www.ncbi.nlm.nih.gov/pubmed/?term=Lane%20D%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Farhat GN](http://www.ncbi.nlm.nih.gov/pubmed/?term=Farhat%20GN%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Freiberg MS](http://www.ncbi.nlm.nih.gov/pubmed/?term=Freiberg%20MS%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Keiding N](http://www.ncbi.nlm.nih.gov/pubmed/?term=Keiding%20N%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Lee JS](http://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20JS%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Prentice R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Prentice%20R%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Tjønneland A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Tj%C3%B8nneland%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Vitolins MZ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Vitolins%20MZ%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Wassertheil-Smoller S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Wassertheil-Smoller%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Strickler HD](http://www.ncbi.nlm.nih.gov/pubmed/?term=Strickler%20HD%5BAuthor%5D&cauthor=true&cauthor_uid=22564867), [Rod NH](http://www.ncbi.nlm.nih.gov/pubmed/?term=Rod%20NH%5BAuthor%5D&cauthor=true&cauthor_uid=22564867). Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. [Cancer Epidemiol Biomarkers Prev.](http://www.ncbi.nlm.nih.gov/pubmed/22564867) 2012 Jul;21(7):1203-12.

Janesick AS, Shioda T, Blumberg B. Transgenerational inheritance of prenatal obesogen exposure. Mol Cell Endocrinol 2014;398:31-5.

JASSO. Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J. 2002 Nov;66(11):987-992.

Jensen MD, Ryan DH, Donato KA, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity 2014;22(S2):S1-S-410

Kanaka-Gantenbein C. [Fetal origins of adult diabetes.](http://www.ncbi.nlm.nih.gov/pubmed/20840260) Ann N Y Acad Sci. 2010 Sep;1205:99-105.

Kramer CK, Zinman B, Retnakaran R. [Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis.](http://www.ncbi.nlm.nih.gov/pubmed/24297192) Ann Intern Med. 2013 Dec 3;159(11):758-69.

Keith SW, Redden DT, Katzmarzyk PT, et all Putative contributors to the secular increase in obesity: exploring the roads less traveled. Int J Obes 2006;30:1585-1594.

Kyle TK, Dhurandhar EJ, Allison DB. Regarding Obesity as a Disease. Endocrinol Metab Clin N Am 2016;45:511-520

Lajous M, Banack HR, Kaufman JS, Hernán MA. Should patients with chronic disease be told to gain weight? The obesity paradox and selection bias. Am J Med. 2015;128: 334–336

Latner, J. D. and A. J. Stunkard 2003. "Getting worse: the stigmatization of obese children." Obes Res 11(3): 452-6.

[Li C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Li%20C%5BAuthor%5D&cauthor=true&cauthor_uid=20381517), [Ford ES](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ford%20ES%5BAuthor%5D&cauthor=true&cauthor_uid=20381517), [Zhao G](http://www.ncbi.nlm.nih.gov/pubmed/?term=Zhao%20G%5BAuthor%5D&cauthor=true&cauthor_uid=20381517), [Croft JB](http://www.ncbi.nlm.nih.gov/pubmed/?term=Croft%20JB%5BAuthor%5D&cauthor=true&cauthor_uid=20381517), [Balluz LS](http://www.ncbi.nlm.nih.gov/pubmed/?term=Balluz%20LS%5BAuthor%5D&cauthor=true&cauthor_uid=20381517), [Mokdad AH](http://www.ncbi.nlm.nih.gov/pubmed/?term=Mokdad%20AH%5BAuthor%5D&cauthor=true&cauthor_uid=20381517). Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005-2006. [Prev Med.](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Preventive+medicine%22%5BJour%5D+AND+51%5Bvolume%5D+AND+18%5Bpage%5D&cmd=detailssearch) 2010 Jul;51(1):18-23.

[Locke AE](http://www.ncbi.nlm.nih.gov/pubmed/?term=Locke%20AE%5BAuthor%5D&cauthor=true&cauthor_uid=25673413), [Kahali B](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kahali%20B%5BAuthor%5D&cauthor=true&cauthor_uid=25673413), [Berndt SI](http://www.ncbi.nlm.nih.gov/pubmed/?term=Berndt%20SI%5BAuthor%5D&cauthor=true&cauthor_uid=25673413), [Justice AE](http://www.ncbi.nlm.nih.gov/pubmed/?term=Justice%20AE%5BAuthor%5D&cauthor=true&cauthor_uid=25673413), [Pers TH](http://www.ncbi.nlm.nih.gov/pubmed/?term=Pers%20TH%5BAuthor%5D&cauthor=true&cauthor_uid=25673413), [Day FR](http://www.ncbi.nlm.nih.gov/pubmed/?term=Day%20FR%5BAuthor%5D&cauthor=true&cauthor_uid=25673413), et al. Genetic studies of body mass index yield new insights for obesity biology. [Nature.](http://www.ncbi.nlm.nih.gov/pubmed/25673413) 2015 Feb 12;518(7538):197-206.

[Loeppke R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Loeppke%20R%5BAuthor%5D&cauthor=true&cauthor_uid=19339899), [Taitel M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Taitel%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19339899), [Haufle V](http://www.ncbi.nlm.nih.gov/pubmed/?term=Haufle%20V%5BAuthor%5D&cauthor=true&cauthor_uid=19339899), [Parry T](http://www.ncbi.nlm.nih.gov/pubmed/?term=Parry%20T%5BAuthor%5D&cauthor=true&cauthor_uid=19339899), [Kessler RC](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kessler%20RC%5BAuthor%5D&cauthor=true&cauthor_uid=19339899), [Jinnett K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Jinnett%20K%5BAuthor%5D&cauthor=true&cauthor_uid=19339899) Health and productivity as a business strategy: a multiemployer study. [J Occup Environ Med.](http://www.ncbi.nlm.nih.gov/pubmed?term=2009%5Bpdat%5D+AND+Loeppke+%5Bauthor%5D&cmd=detailssearch) 2009 Apr;51(4):411-28.

Loos, R. J. Genetic determinants of common obesity and their value in prediction. Best Pract Res Clin Endocrinol Metab 2012. 26(2): 211-226.

Menke A, Rust KF, Fradkin J, Cheng YJ, Cowie CC. Associations Between Trends in Race/Ethnicity, Aging, and Body Mass Index With Diabetes Prevalence in the United States: A Series of Cross-sectional StudiesIncrease in Diabetes Prevalence Over Time Ann Int Med 2014 Sep 2;161(5):328-35.

Moss M. *Salt, Sugar Fat: How the Food Giants Hooked Us.* New York: Random House 2013 p 132

Nagoya Declaration 2015. The 8th Asia-Oceania Conference on Obesity (AOCO 2015). http://www.jasso.or.jp/data/data/pdf/nagoya2015.pdf

National Institutes of Health Consensus Development Panel on the Health Implications of Obesity. Health implications of obesity: National Institutes of Health Consensus Development Conference Statement. *Ann Intern Med.* 1985;103(6 Part 2):1073-1077.

[Neeland IJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Neeland%20IJ%5BAuthor%5D&cauthor=true&cauthor_uid=23687099), [Ayers CR](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ayers%20CR%5BAuthor%5D&cauthor=true&cauthor_uid=23687099), [Rohatgi AK](http://www.ncbi.nlm.nih.gov/pubmed/?term=Rohatgi%20AK%5BAuthor%5D&cauthor=true&cauthor_uid=23687099), [Turer AT](http://www.ncbi.nlm.nih.gov/pubmed/?term=Turer%20AT%5BAuthor%5D&cauthor=true&cauthor_uid=23687099), [Berry JD](http://www.ncbi.nlm.nih.gov/pubmed/?term=Berry%20JD%5BAuthor%5D&cauthor=true&cauthor_uid=23687099), [Das SR](http://www.ncbi.nlm.nih.gov/pubmed/?term=Das%20SR%5BAuthor%5D&cauthor=true&cauthor_uid=23687099), [Vega GL](http://www.ncbi.nlm.nih.gov/pubmed/?term=Vega%20GL%5BAuthor%5D&cauthor=true&cauthor_uid=23687099), [Khera A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Khera%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23687099), [McGuire DK](http://www.ncbi.nlm.nih.gov/pubmed/?term=McGuire%20DK%5BAuthor%5D&cauthor=true&cauthor_uid=23687099), [Grundy SM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Grundy%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=23687099), [de Lemos JA](http://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Lemos%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=23687099). Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. [Obesity (Silver Spring).](http://www.ncbi.nlm.nih.gov/pubmed/23687099)2013;21(9):E439-47.

Nordsiek FW. An epidemiological approach to obesity. Am J Public Health. 1964;54:1689-1698.

Padwal R, Leslie WD, Lix LM, Majumdar SR. Relationship Among Body Fat Percentage, Body Mass Index, and All-Cause Mortality: A Cohort Study. Ann Intern Med. 2016 Apr 19;164(8):532-41.

Pandit R, Mercer JG, Overduin J, la Fleur SE, Adan RAH. Dietary factors affect food reward and motivation to eat. Obes Facts. 2012;5(2):221–42.

Puhl RM, Brownell KD. "Psychosocial origins of obesity stigma: toward changing a powerful and pervasive bias." Obes Rev 2003;4(4): 213-27.

Putnam JJ & Allshouse JE Food Consumption, Prices, and Expenditures, 1970-1997. USDA Food & Agrculture Economic Division, Economic Research Service Bull No 965 p 34

[Radmard AR](http://www.ncbi.nlm.nih.gov/pubmed/?term=Radmard%20AR%5BAuthor%5D&cauthor=true&cauthor_uid=26256899), [Merat S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Merat%20S%5BAuthor%5D&cauthor=true&cauthor_uid=26256899), [Kooraki S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kooraki%20S%5BAuthor%5D&cauthor=true&cauthor_uid=26256899), [Ashraf M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ashraf%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26256899), [Keshtkar A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Keshtkar%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26256899), [Sharafkhah M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Sharafkhah%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26256899), [Jafari E](http://www.ncbi.nlm.nih.gov/pubmed/?term=Jafari%20E%5BAuthor%5D&cauthor=true&cauthor_uid=26256899), [Malekzadeh R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Malekzadeh%20R%5BAuthor%5D&cauthor=true&cauthor_uid=26256899), [Poustchi H](http://www.ncbi.nlm.nih.gov/pubmed/?term=Poustchi%20H%5BAuthor%5D&cauthor=true&cauthor_uid=26256899) Gallstone disease and obesity: a population-based study on abdominal fat distribution and gender differences. [Ann Hepatol.](http://www.ncbi.nlm.nih.gov/pubmed/26256899) 2015 Sep-Oct;14(5):702-9.

[Reyes C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Reyes%20C%5BAuthor%5D&cauthor=true&cauthor_uid=27059260), [Leyland KM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Leyland%20KM%5BAuthor%5D&cauthor=true&cauthor_uid=27059260), [Peat G](http://www.ncbi.nlm.nih.gov/pubmed/?term=Peat%20G%5BAuthor%5D&cauthor=true&cauthor_uid=27059260), [Cooper C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cooper%20C%5BAuthor%5D&cauthor=true&cauthor_uid=27059260), [Arden NK](http://www.ncbi.nlm.nih.gov/pubmed/?term=Arden%20NK%5BAuthor%5D&cauthor=true&cauthor_uid=27059260), [Prieto-Alhambra D](http://www.ncbi.nlm.nih.gov/pubmed/?term=Prieto-Alhambra%20D%5BAuthor%5D&cauthor=true&cauthor_uid=27059260) Association Between Overweight and Obesity and Risk of Clinically Diagnosed Knee, Hip, and Hand Osteoarthritis: A Population-Based Cohort Study. [Arthritis Rheumatol.](http://www.ncbi.nlm.nih.gov/pubmed/27059260) 2016 Aug;68(8):1869-75.

Rosenbaum M, Knight R, Leibel RL.The gut microbiota in human energy homeostasis and obesity. Trends Endocrinol Metab 2015 Sep;26(9):493-501.

Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, Coutinho T, Jensen MD, Roger VL, Singh P, Lopez-Jimenez F. [Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality.](http://www.ncbi.nlm.nih.gov/pubmed/26551006) Ann Intern Med. 2015 Dec 1;163(11):827-35.

[Schnabel RB](http://www.ncbi.nlm.nih.gov/pubmed/?term=Schnabel%20RB%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Yin X](http://www.ncbi.nlm.nih.gov/pubmed/?term=Yin%20X%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Larson MG](http://www.ncbi.nlm.nih.gov/pubmed/?term=Larson%20MG%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Yamamoto JF](http://www.ncbi.nlm.nih.gov/pubmed/?term=Yamamoto%20JF%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Fontes JD](http://www.ncbi.nlm.nih.gov/pubmed/?term=Fontes%20JD%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Kathiresan S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Kathiresan%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Rong J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Rong%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Levy D](http://www.ncbi.nlm.nih.gov/pubmed/?term=Levy%20D%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Keaney JF Jr](http://www.ncbi.nlm.nih.gov/pubmed/?term=Keaney%20JF%20Jr%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Wang TJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20TJ%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Murabito JM](http://www.ncbi.nlm.nih.gov/pubmed/?term=Murabito%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Vasan RS](http://www.ncbi.nlm.nih.gov/pubmed/?term=Vasan%20RS%5BAuthor%5D&cauthor=true&cauthor_uid=23640499), [Benjamin EJ](http://www.ncbi.nlm.nih.gov/pubmed/?term=Benjamin%20EJ%5BAuthor%5D&cauthor=true&cauthor_uid=23640499) Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. [Arterioscler Thromb Vasc Biol.](http://www.ncbi.nlm.nih.gov/pubmed/23640499) 2013 Jul;33(7):1728-33.

Scottish Intercollegiate Guidelines Network (SIGN). Clinical Management of Obesity: A National Clinical Guideline No 15 February 2010

Scully T. New insights for obesity biology. [Nature.](http://www.ncbi.nlm.nih.gov/pubmed?term=Nature%5BJour%5D+AND+518%5Bvolume%5D+AND+197%5Bpage%5D&cmd=detailssearch) 2015 Feb 12;518(7538):197

-206.

Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R,

Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM; Swedish Obese Subjects Study. [Effects of bariatric surgery on mortality in Swedish obese subjects.](https://www.ncbi.nlm.nih.gov/pubmed/17715408) N Engl J Med. 2007;357:741-52

Strawbridge RJ, et al. [New genetic loci link adipose and insulin biology to body fat distribution.](http://www.ncbi.nlm.nih.gov/pubmed/25673412) [Nature.](http://www.ncbi.nlm.nih.gov/pubmed/25673413) 2015 Feb 12;518(7538):197-206. .

Sievenpiper JL, Jenkins DJ, Josse RG, Leiter LA, Vuksan V. [Simple skinfold-thickness measurements complement conventional anthropometric assessments in predicting glucose tolerance.](http://www.ncbi.nlm.nih.gov/pubmed/11237933) Am J Clin Nutr. 2001 Mar;73(3):567-73.

Sjostrom CD, Lissner L, Sjostrom L. Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Swedish Obese Subjects. Obes Res. 1997;5(6):519-530.

[Sumithran P](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sumithran%20P%5BAuthor%5D&cauthor=true&cauthor_uid=22029981), [Prendergast LA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Prendergast%20LA%5BAuthor%5D&cauthor=true&cauthor_uid=22029981), [Delbridge E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Delbridge%20E%5BAuthor%5D&cauthor=true&cauthor_uid=22029981), [Purcell K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Purcell%20K%5BAuthor%5D&cauthor=true&cauthor_uid=22029981), [Shulkes A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Shulkes%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22029981), [Kriketos A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kriketos%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22029981), [Proietto J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Proietto%20J%5BAuthor%5D&cauthor=true&cauthor_uid=22029981) Long-term persistence of hormonal adaptations to weight loss. [N Engl J Med.](https://www.ncbi.nlm.nih.gov/pubmed?term=2011%5Bpdat%5D+AND+Sumithran+%5Bfirst+author%5D&cmd=detailssearch) 2011 Oct 27;365(17):1597-604.

Tsai AG, Williamson DF, Glick HA. Direct medical cost of overweight and obesity in the USA: a quantative systematic review. Obes Rev 2011;12:50-61.

[Tuomilehto H](http://www.ncbi.nlm.nih.gov/pubmed/?term=Tuomilehto%20H%5BAuthor%5D&cauthor=true&cauthor_uid=23079209), [Seppä J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Sepp%C3%A4%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23079209), [Uusitupa M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Uusitupa%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23079209). Obesity and obstructive sleep apnea--clinical significance of weight loss. [Sleep Med Rev.](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sleep+medicine+reviews%22%5BJour%5D+AND+17%5Bvolume%5D+AND+321%5Bpage%5D&cmd=detailssearch) 2013 Oct;17(5):321-9.

Venditti EM, Bray GA, Carrion-Peterson ML, Delahanty LM, Edelstein SL, Hamman RF, Hoskin MA, Knowler WC, Ma Y, for the Diabetes Prevention Research Group. First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. Intern J Obes 2008;32,1537-1664.

Wadd, W. *Cursory remarks on corpulence; or obesity considered as a disease: with a critical examination of ancient and modern opinion, relative to its causes and cure.* London: J. Callow, 1816,

[Wall H](http://www.ncbi.nlm.nih.gov/pubmed/?term=Wall%20H%5BAuthor%5D&cauthor=true&cauthor_uid=22751736), [Smith C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Smith%20C%5BAuthor%5D&cauthor=true&cauthor_uid=22751736), [Hubbard R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hubbard%20R%5BAuthor%5D&cauthor=true&cauthor_uid=22751736) Body mass index and obstructive sleep apnoea in the UK: a cross-sectional study of the over-50s. [Prim Care Respir J.](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Primary+care+respiratory+journal+%3A+journal+of+the+General+Practice+Airways+Group%22%5BJour%5D+AND+21%5Bvolume%5D+AND+371%5Bpage%5D&cmd=detailssearch) 2012 Dec;21(4):371-6.

[Wang YC](http://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20YC%5BAuthor%5D&cauthor=true&cauthor_uid=21872750), [McPherson K](http://www.ncbi.nlm.nih.gov/pubmed/?term=McPherson%20K%5BAuthor%5D&cauthor=true&cauthor_uid=21872750), [Marsh T](http://www.ncbi.nlm.nih.gov/pubmed/?term=Marsh%20T%5BAuthor%5D&cauthor=true&cauthor_uid=21872750), [Gortmaker SL](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gortmaker%20SL%5BAuthor%5D&cauthor=true&cauthor_uid=21872750), [Brown M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Brown%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21872750). Health and economic burden of the projected obesity trends in the USA and the UK. [Lancet.](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lancet+%28London%2C+England%29%22%5BJour%5D+AND+378%5Bvolume%5D+AND+815%5Bpage%5D&cmd=detailssearch) 2011 Aug 27;378(9793):815-25.

Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality I 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083-1096.

Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering” prevalence and correlated of 1 phenotypes among the US population (NHANES 1999-2004) Arch Int Med 2008;168:1617-1624.

Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ). Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. New Engl J Med 2013 Jul 11;369(2):145-54

[Yatsuya H](http://www.ncbi.nlm.nih.gov/pubmed/?term=Yatsuya%20H%5BAuthor%5D&cauthor=true&cauthor_uid=20093637), [Folsom AR](http://www.ncbi.nlm.nih.gov/pubmed/?term=Folsom%20AR%5BAuthor%5D&cauthor=true&cauthor_uid=20093637), [Yamagishi K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Yamagishi%20K%5BAuthor%5D&cauthor=true&cauthor_uid=20093637), [North KE](http://www.ncbi.nlm.nih.gov/pubmed/?term=North%20KE%5BAuthor%5D&cauthor=true&cauthor_uid=20093637), [Brancati FL](http://www.ncbi.nlm.nih.gov/pubmed/?term=Brancati%20FL%5BAuthor%5D&cauthor=true&cauthor_uid=20093637), [Stevens J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Stevens%20J%5BAuthor%5D&cauthor=true&cauthor_uid=20093637); [Atherosclerosis Risk in Communities Study Investigators](http://www.ncbi.nlm.nih.gov/pubmed/?term=Atherosclerosis%20Risk%20in%20Communities%20Study%20Investigators%5BCorporate%20Author%5D). Race- and sex-specific associations of obesity measures with ischemic stroke incidence in the Atherosclerosis Risk in Communities (ARIC) study. [Stroke.](http://www.ncbi.nlm.nih.gov/pubmed/20093637) 2010 Mar;41(3):417-25.